

ASX Announcement

28 September 2023

Cogstate Limited
ABN 80 090 975 723

Level 32
367 Collins Street
Melbourne, Vic, 3000
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

Eisai Japan Announces Dementia Care Support Insurance Including Ancillary Use Of Cogstate Technology (NouKNOW)

Cogstate (ASX:CGS) first announced an agreement with pharmaceutical company Eisai Co., Ltd (Eisai) to distribute Cogstate technology in Japan on 28 August 2019 (please see ASX announcement from that date for full details).

Earlier this week (25 September 2023), Eisai announced that humanized antisoluble aggregated amyloid-beta (A β) monoclonal antibody “LEQEMBI® Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). A copy of the full announcement is available at eisai.com (<https://www.eisai.com/news/2023/pdf/enews202359pdf.pdf>)

Today (28 September 2023), Eisai have announced that they have co-developed (in conjunction with Tokio Marine & Nichido Fire Insurance Co., Ltd – “Tokio Marine”) “Dementia Care Support Insurance” to financially support early detection and early treatment for dementia.

Since August 2019, Eisai and Tokio Marine have promoted, in Japan, initiatives to promote a dementia inclusive society, including the provision since April 2021 of NouKNOW, a digital tool for self-assessment of cognitive function developed by Eisai in conjunction with Cogstate and built upon Cogstate technology.

The newly developed insurance product will provide patients with a lump sum payment in the event of diagnosis of either Mild Cognitive Impairment or Alzheimer’s disease. Additionally, the policy provides the opportunity for policy holders to utilise NowKNOW as an ancillary service, ensuring the support of early detection and early treatment by identifying cognitive decline.

A copy of the full announcement is available at eisai.com (<https://www.eisai.com/news/2023/pdf/enews202360pdf.pdf>)

This announcement was authorised for release by Cogstate CEO, Brad O’Connor.

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com

Important Notices

Past performance

Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

Future performance and forward-looking statements

This announcement contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's business strategies, including the that the results of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its customers which are influenced by factors that are outside of Cogstate's control.

Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Cogstate, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.